{
  "content": "Diagnosis\n\t1. Pancreatic large cell neuroendocrine carcinoma\n\tDate of diagnosis\n\tJanuary 2024\n\n\tTreatment aim\n\tCurative intent\n\n\tSummary of completed treatment and relevant dates\n\n\tSurgery\n\t15 Jan 2024 Diagnostic laparoscopy and biopsy\n\tChemotherapy\n\t1. Carboplatin/Etoposide commenced 01 Feb 2024\n\t2. Completed 4 cycles with excellent response\n\n\tRadiotherapy\n\tNot indicated at present\n\n\tClinical studies\n\tNone\n\n\tCurrent disease status\n\tPartial response to treatment\n\n\tCurrent issues\n\tNone significant\n\n\tSummary of consultation\n\tReviewed today following completion of cycle 4 carboplatin/etoposide. Latest CT shows excellent partial response with 60% reduction in pancreatic primary (now 3.2cm from 8cm) and complete resolution of peritoneal disease. Chromogranin A has normalized from 325 to 42. Performance status remains 1. Blood parameters are satisfactory for continuation of treatment.\n\n\tFurther investigations\n\tCT chest/abdomen/pelvis after cycle 6\n\tChromogranin A monitoring\n\n\tMedication prescribed\n\tContinue with cycles 5-6 carboplatin AUC5/etoposide 100mg/m2\n\n\tFollow up\n\tNext oncology follow up in 3 weeks pre cycle 5\n\n\tRequired GP actions\n\tNone",
  "output": {
    "primary_cancer": {
      "site": "pancreas",
      "year": 2024,
      "month": 1,
      "histopathology_status": "large cell neuroendocrine carcinoma",
      "biomarker_status": "Synaptophysin positive",
      "other_stage": "Stage IIIA",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Diagnostic laparoscopy and biopsy",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started Carboplatin/Etoposide chemotherapy",
          "year": 2024,
          "month": 2
        },
        {
          "type": "laboratory_finding",
          "value": "Chromogranin A elevated at 325",
          "year": 2024,
          "month": 2
        },
        {
          "type": "anatomical_finding",
          "value": "Initial pancreatic primary 8cm with peritoneal disease",
          "year": 2024,
          "month": 2
        },
        {
          "type": "laboratory_finding",
          "value": "Chromogranin A normalized to 42",
          "year": 2024,
          "month": null
        },
        {
          "type": "anatomical_finding",
          "value": "CT shows 60% reduction in pancreatic primary to 3.2cm and complete resolution of peritoneal disease",
          "year": 2024,
          "month": null
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "Performance status 1"
      },
      {
        "type": "investigation_finding",
        "value": "Blood parameters satisfactory for continuing treatment"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Stage IIIA pancreatic neuroendocrine carcinoma showing excellent response to carboplatin/etoposide chemotherapy with significant reduction in disease burden"
      },
      {
        "type": "latest_treatment_response",
        "value": "60% reduction in pancreatic primary and complete resolution of peritoneal disease"
      },
      {
        "type": "update_to_treatment",
        "value": "Continue with cycles 5-6 carboplatin AUC5/etoposide 100mg/m2"
      },
      {
        "type": "planned_investigation",
        "value": "CT chest/abdomen/pelvis after cycle 6 and Chromogranin A monitoring"
      },
      {
        "type": "follow_up_referral",
        "value": "Review in 3 weeks pre cycle 5"
      }
    ]
  }
}